FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Feng Xuan

Co-Founder & Chief Executive Officer Spear Bio Inc.

Tuesday 3rd February 2026

SPEAR UltraDetect™ for Neurodegenerative Biomarker Detection & Monitoring

1:30 pm

A novel immunoassay platform enabling ultra-sensitive detection of neurological biomarker detection
Quantitative plasma pTau 217 measurement with enhanced discrimination of amyloid positivity in both memory clinic and community cohorts
Beyond pTau 217: advancing Alzheimer’s and Parkinson’s disease research with the SPEAR UltraDetect™ biomarker solution